|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
EP1179340A3
(en)
|
1994-09-30 |
2003-05-07 |
INEX Pharmaceutical Corp. |
Compositions for the introduction of polyanionic materials into cells
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
AU719001B2
(en)
|
1994-12-29 |
2000-05-04 |
Massachusetts Institute Of Technology |
Chimeric DNA-binding proteins
|
|
US5695937A
(en)
|
1995-09-12 |
1997-12-09 |
The Johns Hopkins University School Of Medicine |
Method for serial analysis of gene expression
|
|
US7368551B2
(en)
|
1998-06-25 |
2008-05-06 |
The General Hospital Corporation |
De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
ATE353361T1
(de)
|
2000-04-28 |
2007-02-15 |
Sangamo Biosciences Inc |
Gezielten modifikation der chromatinstruktur
|
|
US6919204B2
(en)
|
2000-09-29 |
2005-07-19 |
Sangamo Biosciences, Inc. |
Modulation of gene expression using localization domains
|
|
WO2002057293A2
(en)
|
2001-01-22 |
2002-07-25 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
|
WO2003027247A2
(en)
|
2001-09-24 |
2003-04-03 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
|
WO2003072788A1
(en)
|
2002-02-21 |
2003-09-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
EP1678315B1
(en)
|
2003-09-19 |
2011-08-03 |
Sangamo BioSciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
WO2007086881A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
|
US20110071208A1
(en)
|
2009-06-05 |
2011-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated dicer-substrate interfering rna
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
US20140271550A1
(en)
|
2013-03-14 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015138870A2
(en)
|
2014-03-13 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeted epigenetic modification
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
US11674144B2
(en)
|
2015-04-16 |
2023-06-13 |
California Institute Of Technology |
Fractional regulation of transcription
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
WO2017068077A1
(en)
|
2015-10-20 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and products for genetic engineering
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017083722A1
(en)
|
2015-11-11 |
2017-05-18 |
Greenberg Kenneth P |
Crispr compositions and methods of using the same for gene therapy
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
CA3034369A1
(en)
|
2016-08-19 |
2018-02-22 |
Whitehead Institute For Biomedical Research |
Methods of editing dna methylation
|
|
US20190255106A1
(en)
|
2016-09-07 |
2019-08-22 |
Flagship Pioneering Inc. |
Methods and compositions for modulating gene expression
|
|
MX2019003674A
(es)
|
2016-09-30 |
2021-01-08 |
Univ California |
Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
|
|
US20200149039A1
(en)
|
2016-12-12 |
2020-05-14 |
Whitehead Institute For Biomedical Research |
Regulation of transcription through ctcf loop anchors
|
|
WO2018147343A1
(en)
|
2017-02-07 |
2018-08-16 |
Edigene Corporation |
Method of treating diseases associated with elevated kras expression using crispr-gndm system
|
|
WO2018195555A1
(en)
|
2017-04-21 |
2018-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
|
|
US20230340471A1
(en)
|
2017-04-23 |
2023-10-26 |
Ospedale San Raffaele S.R.L. |
Permanent Epigenetic Gene Silencing
|
|
US11439692B2
(en)
|
2017-05-17 |
2022-09-13 |
Modalis Therapeutics Corporation |
Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
|
|
US11072782B2
(en)
|
2017-07-24 |
2021-07-27 |
Albert-Ludwigs-Universitaet Freiburg |
Construct for epigenetic modification and its use in the silencing of genes
|
|
US20190233805A1
(en)
|
2017-10-04 |
2019-08-01 |
The Regents Of The University Of California |
Targetable proteins for epigenetic modification and methods for use thereof
|
|
US11629342B2
(en)
|
2017-10-17 |
2023-04-18 |
President And Fellows Of Harvard College |
Cas9-based transcription modulation systems
|
|
WO2019084140A1
(en)
|
2017-10-24 |
2019-05-02 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES
|
|
US20210047653A1
(en)
|
2018-01-30 |
2021-02-18 |
The University Of Memphis Research Foundation |
Compositions and methods for regulating a biological process
|
|
KR102922694B1
(ko)
|
2018-04-19 |
2026-02-03 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
유전자 편집을 위한 조성물 및 방법
|
|
US20210284981A1
(en)
|
2018-07-24 |
2021-09-16 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
JP2021534205A
(ja)
|
2018-08-24 |
2021-12-09 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ポリヌクレオチドの空間的構成のためのシステムおよび方法
|
|
EP3861130A4
(en)
|
2018-10-02 |
2022-08-03 |
Sangamo Therapeutics, Inc. |
GENETIC MODULATORS
|
|
TW202521561A
(zh)
|
2019-04-23 |
2025-06-01 |
美商聖加莫治療股份有限公司 |
染色體9開放讀框72基因表現之調節子及其用途
|
|
JP7663513B2
(ja)
|
2019-05-16 |
2025-04-16 |
トラスティーズ オブ ボストン ユニバーシティ |
調節された合成遺伝子発現システム
|
|
MX2021014478A
(es)
|
2019-05-28 |
2022-01-06 |
Astellas Pharma Inc |
Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
|
|
WO2020247883A2
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Deep mutational evolution of biomolecules
|
|
EP3980533A1
(en)
|
2019-06-07 |
2022-04-13 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
EP4010004A4
(en)
|
2019-08-07 |
2023-09-13 |
Altius Institute For Biomedical Sciences |
Compositions and methods for modulation of gene expression
|
|
CA3154759A1
(en)
|
2019-09-23 |
2021-04-01 |
Flagship Pioneering Innovations V, Inc. |
Modulating genomic complexes
|
|
US20220343485A1
(en)
|
2019-10-02 |
2022-10-27 |
Nippon Telegraph And Telephone Corporation |
Video quality estimation apparatus, video quality estimation method and program
|
|
US20230036273A1
(en)
|
2019-11-27 |
2023-02-02 |
The General Hospital Corporation |
System and method for activating gene expression
|
|
EP4069716A1
(en)
*
|
2019-12-06 |
2022-10-12 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
EP4081533A4
(en)
|
2019-12-23 |
2024-03-20 |
The Regents of The University of California |
CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE
|
|
US20240401032A1
(en)
|
2020-05-04 |
2024-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
|
|
AU2021283185A1
(en)
|
2020-06-02 |
2023-01-05 |
The Regents Of The University Of California |
Compositions and methods for gene editing
|
|
CA3189185A1
(en)
|
2020-08-14 |
2022-02-17 |
Mikko Taipale |
Krab fusion repressors and methods and compositions for repressing gene expression
|
|
CA3192654A1
(en)
|
2020-09-01 |
2022-03-10 |
The Board Of Trustees Of The Leland Stanford Junior Unversity |
Synthetic miniature crispr-cas (casmini) system for eukaryotic genome engineering
|
|
US20240209396A1
(en)
|
2020-09-01 |
2024-06-27 |
Huigene Therapeutics Co., Ltd. |
Small cas proteins and uses thereof
|
|
WO2022104159A1
(en)
|
2020-11-13 |
2022-05-19 |
Duke University |
Targeted gene regulation of human immune cells with crispr-cas systems
|
|
WO2022114243A1
(en)
|
2020-11-25 |
2022-06-02 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
WO2022119957A1
(en)
|
2020-12-02 |
2022-06-09 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
KR20230128289A
(ko)
|
2020-12-03 |
2023-09-04 |
스크라이브 테라퓨틱스 인크. |
조작된 클래스 2 유형 v crispr 시스템
|
|
WO2022125843A1
(en)
|
2020-12-09 |
2022-06-16 |
Scribe Therapeutics Inc. |
Aav vectors for gene editing
|
|
KR20240011120A
(ko)
|
2020-12-22 |
2024-01-25 |
크로마 메디슨, 인크. |
후성유전학적 편집을 위한 조성물 및 방법
|
|
CA3207166A1
(en)
|
2021-02-01 |
2022-08-04 |
Angelo Leone Lombardo |
Gene silencing
|
|
WO2022261149A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
IL310116A
(en)
|
2021-07-20 |
2024-03-01 |
Epicrispr Biotechnologies Inc |
Systems and methods for regulating target genes
|
|
WO2023023553A2
(en)
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
|
JP2024535672A
(ja)
|
2021-09-08 |
2024-10-02 |
メタゲノミ，インク． |
クラスｉｉ、ｖ型ｃｒｉｓｐｒ系
|
|
GB2625500B
(en)
|
2021-09-21 |
2026-04-01 |
Scribe Therapeutics Inc |
Engineered CasX repressor systems
|
|
EP4405490A2
(en)
|
2021-09-23 |
2024-07-31 |
Scribe Therapeutics Inc. |
Self-inactivating vectors for gene editing
|
|
WO2023055893A1
(en)
|
2021-09-30 |
2023-04-06 |
Peter Biotherapeutics, Inc. |
Gene regulation
|
|
WO2023093862A1
(en)
|
2021-11-26 |
2023-06-01 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
|
CN116497002A
(zh)
|
2022-01-19 |
2023-07-28 |
中国科学院动物研究所 |
工程化的CasX核酸酶、效应蛋白及其用途
|
|
JP2025507990A
(ja)
|
2022-03-04 |
2025-03-21 |
エピジェニック・セラピューティクス・インコーポレイテッド |
ゲノム編集の組成物及び方法
|
|
WO2023173110A1
(en)
|
2022-03-11 |
2023-09-14 |
Epicrispr Biotechnologies, Inc. |
Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
|
|
WO2023178280A2
(en)
|
2022-03-17 |
2023-09-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for modulating alpha-synuclein expression
|
|
IL316722A
(en)
|
2022-05-01 |
2024-12-01 |
Chroma Medicine Inc |
Compositions and methods for epigenetic regulation of PCSK9 expression
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
GB2634837A
(en)
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
CN114921439B
(zh)
|
2022-06-16 |
2024-04-26 |
尧唐(上海)生物科技有限公司 |
CRISPR-Cas效应子蛋白、其基因编辑系统及应用
|
|
WO2023250148A1
(en)
|
2022-06-23 |
2023-12-28 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic editing
|
|
IL317701A
(en)
|
2022-06-23 |
2025-02-01 |
Chroma Medicine Inc |
Epigenetic editing compositions and methods
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3260110A1
(en)
|
2022-06-24 |
2023-12-28 |
European Molecular Biology Laboratory |
MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
|
|
CN119698469A
(zh)
|
2022-08-11 |
2025-03-25 |
益杰立科(上海)生物科技有限公司 |
一种表观编辑靶点的方法及用途
|
|
KR20250128349A
(ko)
|
2022-12-23 |
2025-08-27 |
에피제닉 테라퓨틱스 피티이 리미티드 |
융합체 및 이의 용도
|
|
PE20252746A1
(es)
|
2023-03-29 |
2025-12-05 |
Scribe Therapeutics Inc |
Composiciones y metodos para el direccionamiento a pcsk9
|
|
WO2024206620A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Messenger rna encoding casx
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|